Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$103.91 USD

103.91
8,283,452

-0.74 (-0.71%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $103.92 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q2

Omnicell's (OMCL) second-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

    Top Ranked Momentum Stocks to Buy for July 24th

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 24th:

      Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo

      Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.

        Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

        We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.

          The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair

          The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair

            Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?

            Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.

              Mark Vickery headshot

              Top Stock Reports for Wells Fargo, IBM & Abbott

              Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT).

                Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up

                Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.

                  Mark Vickery headshot

                  Housing Starts/Permits Disappoint; MS, USB and ABT Beat

                  Morgan Stanley, U.S. Bank and Abbott all beat expectations, but new Housing Starts and Permits numbers were far below expectations.

                    Abbott (ABT) Beats on Earnings and Revenues in Q2

                    Abbott (ABT) gains ground on new product launches and solid overall growth and delivers strong Q2 results.

                      Tracey Ryniec headshot

                      These Companies are Earnings All-Stars

                      It's not easy to beat on earnings nearly every quarter but these 5 companies are doing just that. Can they keep up their winning streaks?

                        Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?

                        According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.

                          Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?

                          Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.

                            Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?

                            Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.

                              Here's Why AbbVie Stock is Good for Your Portfolio's Health

                              Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.

                                The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M

                                The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M

                                  Mark Vickery headshot

                                  Top Stock Reports for Facebook, Amgen & Abbott

                                  Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Amgen (AMGN), and Abbott (ABT).

                                    Sweta Jaiswal headshot

                                    Tap Cardiovascular Devices Market Boom With These 3 Stocks

                                    Consider these three stocks in the rapidly-growing cardiovascular devices market.

                                      Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

                                      Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

                                        Boston Scientific Up on Possible Takeover Bid by Stryker

                                        Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.

                                          Bio-Rad Banks on Solid Global Scenario, Competition Rife

                                          Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.

                                            Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

                                            Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.

                                              The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman

                                              The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman

                                                Abbott Presents Positive Data for AMPLATZER Amulet Device

                                                Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.

                                                  Abbott Presents Positive Study Results for Tendyne Device

                                                  Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.